سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

Role of PI3K/AKT/mTOR pathway as a therapeutic target in estrogen receptor-positive breast cancer

Publish Year: 1397
Type: Conference paper
Language: English
View: 537

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دانلود نمایند.

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

Export:

Link to this Paper:

Document National Code:

MPNI01_069

Index date: 11 June 2019

Role of PI3K/AKT/mTOR pathway as a therapeutic target in estrogen receptor-positive breast cancer abstract

Background and aim: The activation of phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PAM) pathway has been reported in the breast cancer, among which PIK3CA is the most significant gene prevalently mutated in estrogen receptor (ER)-positive breast cancer. Human tumor samples have shown lower ER levels of the PAM signaling pathway, meaning the endocrine resistance. Materials and methods: The articles searched on PubMed database in English was based on the keywords of ER-positive breast cancer, PI3K/AKT/mTOR pathway, Mammalian target of rapamycin, Endocrine resistance and Endocrine therapy. Results: The inhibition of PAM pathway enhanced significantly the expression of ER gene and ER-inducible target genes, and elevated sensitivity to tamoxifen treatment in ER-positive breast cancer cell lines. The PAM pathway as an important intracellular signaling system can cause the cell growth and vitality. Highly activated pathway can affect the tumorigenesis of ER-positive breast cancer and the endocrine therapy resistance. Based on preclinical and clinical trials, the inhibition of PAM pathway can be effective in the endocrine therapy from the first-line setting and beyond in the ER-positive breast cancer.Conclusion: According to the findings, it is pivotal to scrutinize the mechanism of PAM pathway signaling in maintaining the ER-positive breast cancers and starting the endocrine therapy resistance, whose inhibition can be effective to treat the ER-positive breast cancer, suggesting endocrine therapy coupled with PAM pathway inhibition.

Role of PI3K/AKT/mTOR pathway as a therapeutic target in estrogen receptor-positive breast cancer Keywords:

Role of PI3K/AKT/mTOR pathway as a therapeutic target in estrogen receptor-positive breast cancer authors

Jeiran Haghighi

School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Mohammad Amin Dehghani

Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Fatemeh Dehghani

Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Afarin Aghajari

School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran